Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2401872
Max Phase: Preclinical
Molecular Formula: C33H30ClF2N5O6
Molecular Weight: 630.63
Molecule Type: Small molecule
Associated Items:
ID: ALA2401872
Max Phase: Preclinical
Molecular Formula: C33H30ClF2N5O6
Molecular Weight: 630.63
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1ccc2cc3[n+](cc2c1OCCN(CCn1cnc([N+](=O)[O-])c1)Cc1ccc(F)cc1F)CCc1cc2c(cc1-3)OCO2.[Cl-]
Standard InChI: InChI=1S/C33H30F2N5O6.ClH/c1-43-29-5-3-21-12-28-25-15-31-30(45-20-46-31)13-22(25)6-7-39(28)17-26(21)33(29)44-11-10-37(16-23-2-4-24(34)14-27(23)35)8-9-38-18-32(36-19-38)40(41)42;/h2-5,12-15,17-19H,6-11,16,20H2,1H3;1H/q+1;/p-1
Standard InChI Key: BYNQCTKQWZIMOE-UHFFFAOYSA-M
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 630.63 | Molecular Weight (Monoisotopic): 630.2159 | AlogP: 5.05 | #Rotatable Bonds: 11 |
Polar Surface Area: 105.00 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 0 |
#RO5 Violations: 2 | HBA (Lipinski): 11 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: | CX Basic pKa: 6.82 | CX LogP: 1.19 | CX LogD: 1.09 |
Aromatic Rings: 5 | Heavy Atoms: 46 | QED Weighted: 0.11 | Np Likeness Score: -0.40 |
1. Zhang L, Chang JJ, Zhang SL, Damu GL, Geng RX, Zhou CH.. (2013) Synthesis and bioactive evaluation of novel hybrids of metronidazole and berberine as new type of antimicrobial agents and their transportation behavior by human serum albumin., 21 (14): [PMID:23743440] [10.1016/j.bmc.2013.05.007] |
Source(1):